{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:12:00Z","timestamp":1778195520133,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.10231.BD"],"award-info":[{"award-number":["2020.10231.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the era of personalized medicine, pharmacovigilance faces new challenges and opportunities, demanding a shift from traditional approaches. This article delves into the evolving landscape of drug safety monitoring in the context of personalized treatments. We aim to provide a succinct reflection on the intersection of tailored therapeutic strategies and vigilant pharmacovigilance practices. We discuss the integration of pharmacogenetics in enhancing drug safety, illustrating how genetic profiling aids in predicting drug responses and adverse reactions. Emphasizing the importance of phase IV\u2014post-marketing surveillance, we explore the limitations of pre-marketing trials and the necessity for a comprehensive approach to drug safety. The article discusses the pivotal role of pharmacogenetics in pre-exposure risk management and the redefinition of pharmacoepidemiological methods for post-exposure surveillance. We highlight the significance of integrating patient-specific genetic profiles in creating personalized medication leaflets and the use of advanced computational methods in data analysis. Additionally, we examine the ethical, privacy, and data security challenges inherent in precision medicine, emphasizing their implications for patient consent and data management.<\/jats:p>","DOI":"10.1007\/s11096-024-01709-x","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T10:02:24Z","timestamp":1709114544000},"page":"755-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Unveiling the future: precision pharmacovigilance in the era of personalized medicine"],"prefix":"10.1007","volume":"46","author":[{"given":"Lurdes","family":"Silva","sequence":"first","affiliation":[]},{"given":"Teresa","family":"Pacheco","sequence":"additional","affiliation":[]},{"given":"Em\u00edlia","family":"Ara\u00fajo","sequence":"additional","affiliation":[]},{"given":"Rita J.","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Ribeiro-Vaz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6517-6021","authenticated-orcid":false,"given":"Renato","family":"Ferreira-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"7","key":"1709_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrd3501","volume":"10","author":"HG Eichler","year":"2011","unstructured":"Eichler HG, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: a regulator\u2019s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10(7):495\u2013506. https:\/\/doi.org\/10.1038\/nrd3501.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"1709_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40264-014-0194-3","volume":"37","author":"YL Huang","year":"2014","unstructured":"Huang YL, Moon J, Segal JB. A comparison of active adverse event surveillance systems worldwide. Drug Saf. 2014;37(8):581\u201396. https:\/\/doi.org\/10.1007\/s40264-014-0194-3.","journal-title":"Drug Saf"},{"key":"1709_CR3","doi-asserted-by":"publisher","first-page":"204209862093859","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar M, Tawfiq AM, Hassan N, et al. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;11:2042098620938595. https:\/\/doi.org\/10.1177\/2042098620938595.","journal-title":"Ther Adv Drug Saf"},{"issue":"23","key":"1709_CR4","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence\u2014What is it and what can it tell us? N Engl J Med. 2016;375(23):2293\u20137. https:\/\/doi.org\/10.1056\/NEJMsb1609216.","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"1709_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/0098858818789429","volume":"44","author":"S Schneeweiss","year":"2018","unstructured":"Schneeweiss S, Glynn RJ. Real-world data analytics fit for regulatory decision-making. Am J Law Med. 2018;44(2\u20133):197\u2013217. https:\/\/doi.org\/10.1177\/0098858818789429.","journal-title":"Am J Law Med"},{"issue":"8","key":"1709_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/pds.5226","volume":"30","author":"AM Issa","year":"2021","unstructured":"Issa AM, Carleton B, Gerhard T, et al. Pharmacoepidemiology: a time for a new multidisciplinary approach to precision medicine. Pharmacoepidemiol Drug Saf. 2021;30(8):985\u201392. https:\/\/doi.org\/10.1002\/pds.5226.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1709_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.tips.2022.03.009","volume":"43","author":"F De Pretis","year":"2022","unstructured":"De Pretis F, van Gils M, Forsberg MM. A smart hospital-driven approach to precision pharmacovigilance. Trends Pharmacol Sci. 2022;43(6):473\u201381. https:\/\/doi.org\/10.1016\/j.tips.2022.03.009.","journal-title":"Trends Pharmacol Sci"},{"key":"1709_CR8","unstructured":"National Research Council Committee on AFfDaNToD. The National Academies Collection: Reports funded by National Institutes of Health. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. National Academies Press (US) Copyright \u00a9 2011, National Academy of Sciences; 2011."},{"issue":"1","key":"1709_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s1474-4422(19)30269-8","volume":"19","author":"CA Ellis","year":"2020","unstructured":"Ellis CA, Petrovski S, Berkovic SF. Epilepsy genetics: clinical impacts and biological insights. Lancet Neurol. 2020;19(1):93\u2013100. https:\/\/doi.org\/10.1016\/s1474-4422(19)30269-8.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1709_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/14737159.2019.1573144","volume":"19","author":"RS M\u00f8ller","year":"2019","unstructured":"M\u00f8ller RS, Hammer TB, Rubboli G, et al. From next-generation sequencing to targeted treatment of non-acquired epilepsies. Expert Rev Mol Diagn. 2019;19(3):217\u201328. https:\/\/doi.org\/10.1080\/14737159.2019.1573144.","journal-title":"Expert Rev Mol Diagn"},{"issue":"17","key":"1709_CR11","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim J, Hu C, Moufawad El Achkar C, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019;381(17):1644\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1813279.","journal-title":"N Engl J Med"},{"issue":"10","key":"1709_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/omi.2016.0120","volume":"20","author":"C Masimirembwa","year":"2016","unstructured":"Masimirembwa C, Dandara C, Leutscher PD. Rolling out Efavirenz for HIV precision medicine in Africa: Are we ready for pharmacovigilance and tackling neuropsychiatric adverse effects? OMICS. 2016;20(10):575\u201380. https:\/\/doi.org\/10.1089\/omi.2016.0120.","journal-title":"OMICS"},{"issue":"11","key":"1709_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/s2213-8587(18)30052-4","volume":"6","author":"AL Gloyn","year":"2018","unstructured":"Gloyn AL, Drucker DJ. Precision medicine in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6(11):891\u2013900. https:\/\/doi.org\/10.1016\/s2213-8587(18)30052-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1709_CR14","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","volume":"11","author":"Y Jing","year":"2020","unstructured":"Jing Y, Liu J, Ye Y, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020;11(1):4946. https:\/\/doi.org\/10.1038\/s41467-020-18742-9.","journal-title":"Nat Commun"},{"issue":"11","key":"1709_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/gm394","volume":"4","author":"M Schwab","year":"2012","unstructured":"Schwab M, Schaeffeler E. Pharmacogenomics: a key component of personalized therapy. Genome Med. 2012;4(11):93. https:\/\/doi.org\/10.1186\/gm394.","journal-title":"Genome Med"},{"key":"1709_CR16","volume-title":"Bayesian statistics","author":"D Madigan","year":"2011","unstructured":"Madigan D, Ryan P, Simpson S, et al. Bayesian methods in pharmacovigilance. In: Bernardo JM, Bayarri MJ, Berger JO, et al., editors. Bayesian statistics. Oxford: Oxford University Press; 2011."},{"issue":"6450","key":"1709_CR17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/bmj.289.6450.940","volume":"289","author":"DH Lawson","year":"1984","unstructured":"Lawson DH. Pharmacoepidemiology: a new discipline. Br Med J (Clin Res Ed). 1984;289(6450):940\u20131. https:\/\/doi.org\/10.1136\/bmj.289.6450.940.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1709_CR18","unstructured":"European Medicines Agency. ICH E2E Pharmacovigilance planning (Pvp)\u2014scientific guideline. https:\/\/www.ema.europa.eu\/en\/ich-e2e-pharmacovigilance-planning-pvp-scientific-guideline. Accessed 23 Jan 2024."},{"issue":"12","key":"1709_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.tips.2021.09.007","volume":"42","author":"A Bate","year":"2021","unstructured":"Bate A, Stegmann JU. Safety of medicines and vaccines\u2014building next generation capability. Trends Pharmacol Sci. 2021;42(12):1051\u201363. https:\/\/doi.org\/10.1016\/j.tips.2021.09.007.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"1709_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ejca.2008.03.006","volume":"44","author":"CN Oldenhuis","year":"2008","unstructured":"Oldenhuis CN, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44(7):946\u201353. https:\/\/doi.org\/10.1016\/j.ejca.2008.03.006.","journal-title":"Eur J Cancer"},{"key":"1709_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw7745","author":"SP Hey","year":"2020","unstructured":"Hey SP, Gerlach CV, Dunlap G, et al. The evidence landscape in precision medicine. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aaw7745.","journal-title":"Sci Transl Med"},{"issue":"7","key":"1709_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41588-020-0651-0","volume":"52","author":"L Bonomi","year":"2020","unstructured":"Bonomi L, Huang Y, Ohno-Machado L. Privacy challenges and research opportunities for genomic data sharing. Nat Genet. 2020;52(7):646\u201354. https:\/\/doi.org\/10.1038\/s41588-020-0651-0.","journal-title":"Nat Genet"},{"issue":"10","key":"1709_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/FPC.0b013e3283649b9a","volume":"23","author":"DK Hall-Flavin","year":"2013","unstructured":"Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genom. 2013;23(10):535\u201348. https:\/\/doi.org\/10.1097\/FPC.0b013e3283649b9a.","journal-title":"Pharmacogenet Genom"},{"key":"1709_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/clep.S289031","volume":"13","author":"AL Vuorinen","year":"2021","unstructured":"Vuorinen AL, Lehto M, Niemi M, et al. Pharmacogenetics of anticoagulation and clinical events in warfarin-treated patients: a register-based cohort study with biobank data and national health registries in Finland. Clin Epidemiol. 2021;13:183\u201395. https:\/\/doi.org\/10.2147\/clep.S289031.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"1709_CR25","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1080\/09546634.2021.1937480","volume":"33","author":"JY Heo","year":"2022","unstructured":"Heo JY, Cho MK, Kim S. Data mining for detecting signals of adverse drug reaction of doxycycline using the Korea adverse event reporting system database. J Dermatolog Treat. 2022;33(4):2192\u20137. https:\/\/doi.org\/10.1080\/09546634.2021.1937480.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1709_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajhg.2018.05.010","volume":"103","author":"JH Son","year":"2018","unstructured":"Son JH, Xie G, Yuan C, et al. Deep phenotyping on electronic health records facilitates genetic diagnosis by clinical exomes. Am J Hum Genet. 2018;103(1):58\u201373. https:\/\/doi.org\/10.1016\/j.ajhg.2018.05.010.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1709_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-022-01494-9","volume":"21","author":"E Karagiannidis","year":"2022","unstructured":"Karagiannidis E, Moysidis DV, Papazoglou AS, et al. Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease. Cardiovasc Diabetol. 2022;21(1):70. https:\/\/doi.org\/10.1186\/s12933-022-01494-9.","journal-title":"Cardiovasc Diabetol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01709-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T18:41:24Z","timestamp":1716921684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01709-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1709"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01709-x","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest. This collaborative work upholds the integrity of professional ethics and maintains the independence of each author in their respective roles within the regulatory and pharmaceutical sectors. IRV and RFS, representing the Porto Pharmacovigilance Centre, and RJD, from Bayer Portugal, affirm their commitment to these standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}